Nurses in the Cancer Clinical Research Unit

 

Clinical Trials — Breast Cancer

                                                                                            Click on trial for description and contact information.

 

Study of XL184 in Adults with Advanced Solid Tumors NEW

 

Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel and Trastuzumab Followed by Doxorubicin-Cyclophosphamide in Patients With Locally Advanced Breast Cancer

 

A Phase I/II Study of R115777 (Tipifarnib, Zarnestra) plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer (This study is on-going but is no longer recruiting participants.)

 

A Phase II Randomized, Double-Blind, Multi-Center Study of Exemestane with and without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase Inhibitor

 

A Phase II Two-Arm, Double-Blind, Multi-Center, Randomized Study of the Combination of Oral WX-671 plus Capecitabine vs. Capecitabine Monotherapy in First-Line HER2-Negative Metastatic Breast Cancer (This study is on-going but is no longer recruiting participants.)


       

A Phase I Dose-Escalation, Multi-Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients with Advanced Solid Malignancies Including Phase II Expansion Arms in Patients with Either HER2-Positive or ER-Positive Locally Advanced or Metastatic Breast Cancer

 

A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumor

 

For more information or to refer a patient, contact:

Pam Bourbo, RN, MPH, OCN, CCRC

manager

Cancer Clinical Research Unit

(706) 721-2730

pbourbo@mcg.edu


 

[Back to Top]

Revised December 22, 2009.  Please send comments, suggestions or questions about this page to Cancer Team, cancer@mcg.edu.